摘要
目的比较达比加群和华法林治疗高出血风险非瓣膜性房颤患者(NVAF)的临床获益。方法纳入2016年5月31日至2019年5月31日在郑州大学第一附属医院住院且至少服用1种研究药物的高出血NVAF患者进行回顾性分析。通过疗效和安全性评估达比加群组和华法林组的临床获益。结果共纳入973例高出血风险的患者,其中达比加群组514例,华法林组459例。81例(15.8%)达比加群组患者和88例(19.2%)华法林组患者出现主要疗效终点(非劣效性P<0.001)。36例(7.00%)达比加群组患者和55例(11.98%)华法林组患者出现安全性终点(P<0.05)。结论在高出血NVAF患者中,达比加群在预防卒中和非中枢性栓塞方面不劣于华法林,达比加群在减少致命出血和关键器官出血方面优于华法林。
Objective To compare the clinical benefits of dabigatran and warfarin in patients with nonvalvular atrial fibrillation(NVAF)with high bleeding risk.Methods A retrospective study was conducted on patients with high bleeding risk NVAF who were hospitalized at the First Affiliated Hospital of Zhengzhou University between May 31,2016 and May 31,2019 and who took at least dabigatran and warfarin.The clinical benefits of both drugs were assessed by efficacy benefit and safety risk.Results A total of 973 patients with high bleeding risk were enrolled,including 514 in the dabigatran group and 459 in the warfarin group.Results of the primary efficacy benefit endpoint were obtained from 81 patients(15.8%)in the dabigatran group and 88(19.2%)in the warfarin group(P<0.001 for noninferiority).The principal safety end points were observed in 36 patients(7.00%)in the dabigatran group and in 55 patients(11.98%)in the warfarin group(P<0.05).Conclusion Dabigatran is noninferior to warfarin in the prevention of stroke and systemic embolism in patients with high blood NVAF.Dabigatran is superior to warfarin in reducing fatal bleeding and bleeding in critical organs.
作者
刘鹏辉
何飞
LIU Penghui;HE Fei(Department of Cardiology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)
出处
《河南医学研究》
CAS
2022年第5期782-786,共5页
Henan Medical Research
基金
河南省科技攻关计划项目(182102310160)
河南省医学科技攻关计划省部共建备选项目(2018010001)。
关键词
达比加群
华法林
非瓣膜性房颤
高出血
临床获益
dabigatran
warfarin
nonvalvular atrial fibrillation
high bleeding risk
clinical benefit
